-
Flow cytometry with anti-diffraction light sheet (ADLS) by spatial light modulation
Authors:
Yanyan Gong,
Ming Zeng,
Yueqiang Zhu,
Shangyu Li,
Wei Zhao,
Ce Zhang,
Tianyun Zhao,
Kaige Wang,
Jiangcun Yang,
Jintao Bai
Abstract:
Flow cytometry is a widespread and powerful technique, whose resolution is determined by its capacity to accurately distinguish fluorescently positive populations from negative ones. However, most informative results are discarded while performing the measurements of conventional flow cytometry, e.g., the cell size, shape, morphology, and distribution or location of labeled exosomes within the unp…
▽ More
Flow cytometry is a widespread and powerful technique, whose resolution is determined by its capacity to accurately distinguish fluorescently positive populations from negative ones. However, most informative results are discarded while performing the measurements of conventional flow cytometry, e.g., the cell size, shape, morphology, and distribution or location of labeled exosomes within the unpurified biological samples. We, herein, propose a novel approach using an anti-diffraction light sheet with anisotroic feature to excite fluorescent tags. Constituted by an anti-diffraction Bessel-Gaussian beam array, the light sheet is 12 $μ$m wide, 12 $μ$m high, with a thickness of $~ 0.8 μ$m. The intensity profile of the excited fluorescent signal can, therefore, reflect the size and allow samples in the range from O(100 nm) to 10 $μ$m (e.g., blood cells) to be transported via hydrodynamic focusing in a microfluidic chip. The sampling rate is 500 kHz provides a capability of high throughput without sacrificing the spatial resolution. Consequently, the proposed anti-diffraction light-sheet flow cytometry (ADLSFC) can obtain more informative results than the conventional methodologies, and is able to provide multiple characteristics (e.g., the size and distribution of fluorescent signal) helping to distinguish the target samples from the complex backgrounds.
△ Less
Submitted 23 January, 2023;
originally announced January 2023.
-
Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods
Authors:
Xi Yang,
Yan Gong,
Nida Waheed,
Keith March,
Jiang Bian,
William R. Hogan,
Yonghui Wu
Abstract:
Cardiotoxicity related to cancer therapies has become a serious issue, diminishing cancer treatment outcomes and quality of life. Early detection of cancer patients at risk for cardiotoxicity before cardiotoxic treatments and providing preventive measures are potential solutions to improve cancer patients's quality of life. This study focuses on predicting the development of heart failure in cance…
▽ More
Cardiotoxicity related to cancer therapies has become a serious issue, diminishing cancer treatment outcomes and quality of life. Early detection of cancer patients at risk for cardiotoxicity before cardiotoxic treatments and providing preventive measures are potential solutions to improve cancer patients's quality of life. This study focuses on predicting the development of heart failure in cancer patients after cancer diagnoses using historical electronic health record (EHR) data. We examined four machine learning algorithms using 143,199 cancer patients from the University of Florida Health (UF Health) Integrated Data Repository (IDR). We identified a total number of 1,958 qualified cases and matched them to 15,488 controls by gender, age, race, and major cancer type. Two feature encoding strategies were compared to encode variables as machine learning features. The gradient boosting (GB) based model achieved the best AUC score of 0.9077 (with a sensitivity of 0.8520 and a specificity of 0.8138), outperforming other machine learning methods. We also looked into the subgroup of cancer patients with exposure to chemotherapy drugs and observed a lower specificity score (0.7089). The experimental results show that machine learning methods are able to capture clinical factors that are known to be associated with heart failure and that it is feasible to use machine learning methods to identify cancer patients at risk for cancer therapy-related heart failure.
△ Less
Submitted 1 October, 2019;
originally announced October 2019.
-
Tumor Microenvironment-based Gene Signatures Divides Novel Immune and Stromal Subgroup Classification of Lung Adenocarcinoma
Authors:
Zihang Zeng,
Jiali Li,
Nannan Zhang,
Xueping Jiang,
Yanping Gao,
Liexi Xu,
Xingyu Liu,
Jiarui Chen,
Yuke Gao,
Linzhi Han,
Jiangbo Ren,
Yan Gong,
Conghua Xie
Abstract:
Tumor microenvironment has complex effects on tumorigenesis and metastasis. However, there is still a lack of comprehensive understanding of the relationship among molecular and cellular characteristics in tumor microenvironment, clinical prognosis and immunotherpy response. In this study, the immune and stromal (non-immune) signatures of tumor microenvironment were integrated to identify novel su…
▽ More
Tumor microenvironment has complex effects on tumorigenesis and metastasis. However, there is still a lack of comprehensive understanding of the relationship among molecular and cellular characteristics in tumor microenvironment, clinical prognosis and immunotherpy response. In this study, the immune and stromal (non-immune) signatures of tumor microenvironment were integrated to identify novel subgroups of lung adenocarcinoma by eigendecomposition and extraction algorithms of bioinformatics and machine learning, such as non-negative matrix factorization and multitask learning. Tumors were classified into 4 groups according to the activation of immunity and stroma by novel signatures. The 4 groups had different mutation landscape, molecular, cellular characteristics and prognosis, which have been validation in 6 independent data sets containing 1551 patients. High-immune and low-stromal activation group links to high immunocyte infiltration, high immunocompetence, low fibroblasts, endothelial cells, collagen, laminin, tumor mutation burden, and better overall survival. We developed a novel model based on tumor microenvironment by integrating immune and stromal activation, namely PMBT (prognostic model based on tumor microenvironment). The PMBT showed the value to predict overall survival and immunotherapy responses.
△ Less
Submitted 10 May, 2019;
originally announced May 2019.
